AGA Center for Diagnostics & Therapeutics
Drug development is a complex, time-consuming and expensive process requiring the cooperation of various stakeholders. To help facilitate this process, the AGA Center for Diagnostics and Therapeutics provides objective, independent guidance to companies, regulators, investors and health-care professionals on the development of new therapies and diagnostic tests for digestive disorders.
Expertise and Opportunities
• Identification of Experts and Organization of Expert Meetings
• Clinical Study Design and Endpoint Development
• Development of Educational Programs and Resources
We invite AGA partners to suggest other issues facing the drug and diagnostic industries related to clinical development and regulatory approval.
Scientific Advisory Board
Colin W. Howden, MD, AGAF, Chair
University of Tennessee Health Science Center, Memphis
Tara A. Altepeter, MD, FDA Liaison*
Food and Drug Administration, Silver Spring, MD
J. Summer Bell III, MD, AGAF
Gastroenterology Ltd., Virginia Beach, VA
Glenn T. Furuta, MD
Children’s Hospital Colorado, Aurora
M. Scott Harris, MD, AGAF
Avaxia Biologics and Georgetown University, Washington, DC
Rajeev Jain, MD, AGAF, Governing Board Liaison
Texas Digestive Disease Consultants, Dallas
Loren Laine, MD, AGAF
Yale University School of Medicine, Fairfield, CT
Gary R. Lichtenstein, MD, AGAF
University of Pennsylvania, Philadelphia
Fred Poordad, MD
University of Texas Health Science Center, San Antonio
Debra G. Silberg, MD, PhD
Shire Pharmaceuticals, Wayne, PA
Nimish B. Vakil, MD, AGAF
University of Wisconsin Medical School, Summit, WI
Teresa L. Wright, MD, AGAF
Genentech, San Francisco, CA
*Denotes non-voting member.
Are you ready to take the next step?
To learn more about the center, please contact Alison Kim, senior director of research and innovation.